Sociodemographic, clinical and therapeutic factors as predictors of life quality impairment in psoriasis: A cross-sectional study in Italy

被引:7
作者
Scala, Emanuele [1 ,2 ]
Kaczmarczyk, Robert [3 ]
Zink, Alexander [3 ,4 ]
Balato, Anna [5 ]
机构
[1] Karolinska Inst, Dept Med Solna, Div Dermatol & Venereol, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Ctr Mol Med, S-17176 Stockholm, Sweden
[3] Tech Univ Munich, Sch Med, Dept Dermatol & Allergy, Munich, Germany
[4] Karolinska Univ Hosp, Dept Med Solna, Dermatol & Venerol Unit, Stockholm, Sweden
[5] Univ Campania Luigi Vanvitelli, Dermatol Unit, Naples, Italy
关键词
biological therapy; comorbidities; life quality; psoriasis; sociodemographic factors; OF-LIFE; PREVALENCE; SECUKINUMAB; COMORBIDITIES; DEPRESSION; THERAPIES; ARTHRITIS; ISSUES; RISK; SKIN;
D O I
10.1111/dth.15622
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Psoriasis is a chronic inflammatory skin disease showing a high burden due to its aesthetic, social, psychological, and quality of life (QoL) implications which also affect patient-physician relationship and, consequently, the adherence to treatments. Limited data on the natural history of psoriasis and factors predicting its prognosis are available. The aim of this study was to investigate patients' global characteristics, including treatments, associated with QoL impairment in psoriasis. Questionnaires evaluating sociodemographic features and Dermatology Life Quality Index (DLQI) were administered to patients. Multiple regression analysis was performed to evaluate factors associated with a large effect on patient's life (DLQI > 10), moderate effect on patient's life (DLQI >= 6 <= 10), small effect on patient's life (DLQI >= 2 < 6), and no effect on patient's life (DLQI < 2). Overall, 1052 consecutive patients affected by mild-to-severe psoriasis were recruited. Our logistic regression analysis showed that the influencing factors for a large effect on QoL were living in Southern Italy, depression, psoriatic arthritis, and psoriasis localization on facial, intertriginous, palmoplantar, trunk and scalp regions. For a moderate effect on patient's life, phototherapy and non-biological systemic therapies resulted to be the predictive factors. Mild psoriasis, living in social housing and the isolated involvement of scalp psoriasis had a small effect on QoL. Lastly, mild psoriasis and current biological therapies including anti-IL-12/23, anti-IL-17, and anti-TNF-alpha were positively associated with no life quality impairment. Perceived quality of life impairment in psoriasis not only depends on the skin disease but rather on patients ' global characteristics. Therefore, the individual background of these patients should be respected in the selection of treatment options.
引用
收藏
页数:9
相关论文
共 42 条
  • [11] Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis
    Fortune, DG
    Richards, HL
    Corrin, A
    Taylor, RJ
    Griffiths, CEM
    Main, CJ
    [J]. JOURNAL OF BEHAVIORAL MEDICINE, 2003, 26 (03) : 211 - 224
  • [12] Treatment Approaches to Moderate to Severe Psoriasis
    Gisondi, Paolo
    Del Giglio, Micol
    Girolomoni, Giampiero
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (11):
  • [13] Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
    Gottlieb, Alice
    Sullivan, John
    van Doorn, Martijn
    Kubanov, Alexey
    You, Ruquan
    Parneix, Anne
    Hugot, Sophie
    Milutinovic, Marina
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (01) : 70 - 80
  • [14] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    Griffiths, Christopher E. M.
    Reich, Kristian
    Lebwohl, Mark
    van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Cameron, Gregory S.
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta J.
    Ball, Susan
    Braun, Daniel K.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian J.
    Papp, Kim
    [J]. LANCET, 2015, 386 (9993) : 541 - 551
  • [15] Han CL, 2011, J DRUGS DERMATOL, V10, P843
  • [16] Translating the science of quality of life into practice: What do dermatology life quality index scores mean?
    Hongbo, Y
    Thomas, CL
    Harrison, MA
    Salek, MS
    Finlay, AY
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (04) : 659 - 664
  • [17] Are Patients with Psoriasis and Psoriatic Arthritis Undertreated? A Population-Based Study from Southern Italy
    Ingrasciotta, Ylenia
    Isgro, Valentina
    Ientile, Valentina
    Tari, Michele
    Trifiro, Gianluca
    Guarneri, Claudio
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (15)
  • [18] Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis
    Iskandar, I. Y. K.
    Ashcroft, D. M.
    Warren, R. B.
    Lunt, M.
    McElhone, K.
    Smith, C. H.
    Reynolds, N. J.
    Griffiths, C. E. M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : 1410 - 1421
  • [19] Relation between the Peripherofacial Psoriasis and Scalp Psoriasis
    Kim, Kyung Ho
    Ahn, Ji Young
    Park, Mi Youn
    Youn, Jai Il
    [J]. ANNALS OF DERMATOLOGY, 2016, 28 (04) : 422 - 426
  • [20] Economic burden of comorbidities in patients with psoriasis is substantial
    Kimball, A. B.
    Guerin, A.
    Tsaneva, M.
    Yu, A. P.
    Wu, E. Q.
    Gupta, S. R.
    Bao, Y.
    Mulani, P. M.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 (02) : 157 - 163